Home
overview
Identifying failing compounds early is vital in saving resources and bringing forward safer and more potential candidates to the market so that you can gain a greater return on investment.

At SMi’s latest international pharmaceuticals conference ‘Pharmacotoxicology’, taking place on the 29th & 30th October at the Hatton, London, we have done all the research on the current issues in pharmacotoxicology for you so that in just 2 days you can gain all the latest information on this subject.

SMi’s Pharmacotoxicology conference offers you a top-level forum to discuss the ‘hot’ topics on this subject and will focus on the challenges faced in drug safety and evaluation. The conference will look at the bottlenecks in assessing metabolism and toxicity of new pharmaceuticals, including pre-clinical safety, and strategies to improve toxicological testing. It will also look at how recent advances in toxigenomics and predictive toxicology can be utilised to reduce the number of drugs that fail during clinical trials.

Our speakers at this conference are experts in their fields and will present strategies on how the drug development process can be improved by throughput toxicology screening and metabonomics, for greater speed and efficiency of toxicological testing.

There will also be plenty of networking opportunities available, allowing you to discuss the main issues with colleagues from all over the world.

So don’t miss out on this excellent opportunity to gain extra knowledge, register today!

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Dr Gerhard Gross

Dr Gerhard Gross, Head, ADME, Novartis

9:10 STREAMLINING THE ASSESSMENT OF PRODUCT SAFETY IN THE CLINICAL DEVELOPMENT SETTING

Dr Ebiere Bolodeoku

Dr Ebiere Bolodeoku, Senior Medical Advisor, International Clinical Safety, Europe, Amgen

  • Strengthening links between pre-clinical and clinical development
  • Anticipating risk assessment
  • Targeted safety evaluation
  • Enhancing the involvement of toxicologists & clinical investigators
  • 9:40 FUNDAMENTALS OF PHARMACOTOXICOLOGY

    Dr Johan Gabrielsson

    Dr Johan Gabrielsson, Senior Principal Scientist, AstraZeneca R & D

  • The role of ADME in drug discovery and early development
  • What is exposure and how do we use it?
  • Interpretation of toxicity data and extrapolation across species
  • Evaluating safety through the process
  • Dose-response-time data analysis when systemic exposure is lacking
  • Meeting regulatory requirements
  • 10:20 REDUCING FAILURE RATES

    Dr David Leahy

    Dr David Leahy, Director, Cyprotex

  • Virtual screening methods for early evaluation of libraries
  • Knowledge base management for continuous improvement
  • Strategies to save time and money
  • Integration of data and models for prediction of human outcomes
  • Simulation for candidate selection and clinical trial design
  • 11:00 Morning Coffee

    11:20 FORMULATION CONSIDERATIONS FOR IN VIVO STUDIES

    Dr Luigi G Martini

    Dr Luigi G Martini, Team Leader, Dosage Form Design, GlaxoSmithKline

  • Factors affecting oral absorption
  • Formulation to enhance absorption
  • Alignment with dosage to humans
  • How to deal with impurities/degradation products
  • Novel delivery systems
  • 12:00 TOXICOPROTEOMICS USING THE PROTEINCHIP® SYSTEM

    Dr Huw Davies

    Dr Huw Davies, Manager, European Biomarker Discovery Centre, Ciphergen Biosystems

  • Sample handling and protein detection
  • Advantages and limitations vs. conventional techniques
  • Pattern recognition software for data reduction and multi-marker analysis
  • Methodologies for purification and characterisation of candidate biomarkers
  • Advances in automation for high-throughput proteomics
  • 12:45 Networking Lunch

    14:00 WHAT IS PREDICTIVE TOXICOLOGY?

    Dr Paul Trennery

    Dr Paul Trennery, Vice President, Worldwide Safety Assessment, GlaxoSmithKline R & D

  • Defining concepts and principles
  • New approaches to hazard identification
  • Comprehensive risk assessment of drug candidates
  • Toxigenomics: revolutionising toxicology
  • Improving drug safety
  • 14:40 INTEGRATION OF PROTEOMICS AND PREDICTIVE TOXICOLOGY

    Dr Sandy Kennedy

    Dr Sandy Kennedy, Director, Pharmacoproteomics & Preclinical Development, Oxford Glycosciences

  • Application of toxicology information
  • Utilising proteomics in toxicology problem solving
  • Current challenges
  • Proteomic biomarkers
  • Screening for early selection
  • Solving toxicity issues
  • 15:20 Afternoon Tea

    15:40 UTILISING GENE EXPRESSION PROFILING

    Mark Porter

    Mark Porter, Associate Director, Toxicology Bioinformatics, GeneLogic

  • Open and closed system gene expression technologies
  • Multiple species approach
  • Building reference database for in vivo and in vitro use
  • Entire genome assayed for predictive qualities
  • Prediction of toxicity across compound classes
  • Discrimination of individual compounds and classes
  • 16:20 TOXIGENOMIC STRATEGIES

    Dr Elizabeth Foot

    Dr Elizabeth Foot, Pharmacogenetic Scientist, New Product Development, GlaxoSmithKline R & D

  • Needs of early clinical drug development
  • Integrating pharmacogenetics, transcriptomics & proteomics
  • Improving drug safety
  • Safety assessment for the future
  • 17:00 Chairman’s Closing Remarks and Close of Day One

    17:10 Drinks Reception for Delegates & Speakers

    8:30 Re-registration and Coffee

    9:00 Chairman's Opening Remarks

    Dr John Connelly

    Dr John Connelly, Director, Biology, Metabometrix

    9:10 IN SILICO METHODS FOR TOXICITY AND ADME PREDICTION

    Dr Anita White

    Dr Anita White, Group Leader, In Silico ADME/Tox, Global Metabolism & Investigative Services, Pharmacia

  • The role of in silico prediction in product development
  • Benefits of early ADME
  • Reducing the failure rate
  • Statistical analysis of model prediction
  • 9:40 IMPROVING TOXICOLOGICAL DATA MANAGEMENT

    Dr H. Ralph Snodgrass

    Dr H. Ralph Snodgrass, President & Chief Executive Officer, VistaGen

  • Enabling early toxicology and efficacy evaluation
  • Managing toxicology: prioritisation and optimisation
  • Improving the quality and speed of decision-making in the non-clinical evaluation stage
  • Changing the focus to promising drug leads with favourable molecular toxicological characteristics
  • Helping safer drugs reach the market
  • 10:20 COMPUTATIONAL AND DATABASE APPROACHES

    Dr Dale Johnson

    Dr Dale Johnson, Chief Scientific Officer, ddPlatform LLC

  • The application of chem-tox informatics in drug discovery
  • Algorithms for converting toxicology data into focused databases
  • Comprehensive data mining approaches
  • Statistical correlations of toxicity with chemical structure in large datasets
  • Designing virtual chemical libraries using toxicology information
  • Predicting the impact of optimisation schemes on both efficacy and toxicity
  • 11:20 IN VITRO BIOAVAILABILITY, METABOLISM & DRUG EVALUATION

    Dr Florence Salmon

    Dr Florence Salmon, Head, Kinetics & Metabolism, TNO Pharma

  • In vitro techniques for predicting metabolic fate and bioavailability
  • Integrating in vitro data in PBPK models
  • Predicting oral bioavailability from in vitro data
  • Evaluating the impact of metabolism on kinetics
  • Clinical relevance of in vitro drug-drug interactions
  • 12:00 METABOLIC DRUG-DRUG INTERACTIONS

    Dr Louis Leung

    Dr Louis Leung, Principal Research Scientist, Drug Metabolism, Wyeth-Ayerst Research

  • The importance of profiling for drug safety
  • The clinical significance of metabolic drug-drug interactions
  • Role of hepatic and pre-hepatic metabolism and drug transporters
  • Strategies in early discovery
  • In vitro approaches in discovery and development
  • In vitro - in vivo correlation
  • 12:45 Networking Lunch

    14:00 DRUG METABOLISM

    Dr Rae Yuan

    Dr Rae Yuan, Associate Clinical Director, Department of Clinical Pharmacology, F. Hoffman-La Roche

  • Understanding the kinetic profile of a drug
  • Critical issues in predicting metabolism-based drug interactions
  • Importance of studying drug metabolism for gaining drug approval
  • 14:40 COMPUTER ASSISTED APPROACHES FOR DRUG METABOLISM PREDICTION

    Dr Patrizia Crivori

    Dr Patrizia Crivori, Scientist, Global Metabolism & Investigative Sciences, Pharmacia

  • Speed up ‘hit-to-lead’
  • Current in silico approaches for drug metabolism prediction
  • CYP450 inhibition and drug-drug interactions
  • Examples of in silico models
  • Impact on the discovery process
  • 15:20 Afternoon Tea

    15:40 IMPROVING THE THROUGHPUT OF TOXICITY SCREENING

    Dr Erik Jongedijk

    Dr Erik Jongedijk, Director, Business Development, Marketing & Sales, Europe, Phase-1 Molecular Toxicology

  • Applications of throughput technology to pharmacotoxicology
  • Benefits of miniaturisation
  • Methodologies for measuring toxicity
  • Tools to establish a best practice for toxicity testing
  • Improving the drug development process
  • 16:20 METABONOMIC APPROACHES TO SAFETY & EFFICACY ASSESSMENT

    Dr John Connelly

    Dr John Connelly, Director, Biology, Metabometrix

  • Introduction to metabonomics
  • Toxicological applications of metabonomics
  • Practical aspects
  • Building NMR-PR models for toxicological prediction
  • Metabonomics in the pharmaceuticals industry
  • Current developments and future approaches
  • 17:00 Chairman's Closing Remarks and Close of Conference

    +

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.